spain: business opportunities in the biotechnology sector · spain ranks 3rd in europe in ratio of...

Spain: Business

Opportunities in the

Biotechnology sector

Ana AriasINVEST IN SPAINDavid FernándezASEBIO

ILSI-Biomed 2010 Conference Tel-Aviv

� Why Spain?

� Main reason to invest in Spain

� Business opportunities

� The biotech sector

General Contents

� The biotech sector

� About ASEBIO and INVEST IN SPAIN

2

Why Spain?

Why Spain?

“Spain is fast becoming a leader in innovation, generating

advanced solutions in the industries of aerospace, renewable energy . . .

biotechnology . . . and civil engineering. Spanishfirms are innovators in the field of public-works finance

Source: www.genomeweb.com; www.technologyreview.com

4

firms are innovators in the field of public-works finance

and management, where six of the world’s top ten companies are fromSpain. Where innovation thrives, so will the successful globalenterprises of the 21st century”.

Technology Review (a magazine), Massachusetts Institute of Technology (MIT)

Spain is the world leader in organ transplants

� Spain is the top country worldwide in organ donations and transplants.

� Spain participates in various international projects via the Spanish National Transplant Organisation (ONT in Spanish).

Did you know that....?

Spanish).

Spanish Transplant Organisation (ONT)

Source: Website of the Spanish Transplant Organisation www.ont.es

In 2008 the WHO designated the ONT as acollaboration centre for organ donationsand transplants.

5

Solid Basic Science: Spain is 5th worldwide in scientificproduction, especially biochemistry and molecular biology.

Integrated Healthcare System: Spain has an extensivenetwork of university hospitals, both public and private, backedby leading-edge research centres. The system is ideal fortranslational medicine and discovering new drugs and advancedtherapies.

Why Spain?

6

therapies.

Emerging Biotech Industry: biotech companies are growingfaster here than in other countries. Spain is providing strongsupport for the surge in biotechnology and its lateral applicationto other sectors.

Strong Government Support: Spain’s technology fund isfocused on providing foreign companies with financial aid. Privateinvestment will achieve higher returns with the help of subsidiesand public sector aids.

Excellent infrastructure for innovation: exponential growth ofscience and technology parks, research centres and institutes oftechnology. Spain’s infrastructure also incorporates the latesttechnology for life science projects.

Highly qualified workforce: in some areas of Spain thepercentage of workers with post-graduate studies is higher thanthe European average. There is a surplus of talent for competitiveand innovative projects.

Why Spain?

7

and innovative projects.

Favourable cost-benefit ratio of human capital: the cost perhour is less than average for EU25. Salaries are lower but theattraction of working on scientific or biotech projects is highbecause there are few innovative jobs.

Excellent quality of life: Spain is one of the top 10 countries interms of quality of life and is constantly chosen by foreigners as aplace to live and work. Apart from its stability the servicesavailable and the business environment attract many foreigncompanies.

Main reasons to invest in Spain

� International Business Hub� International Business Hub� Incentives programmes� Human capital� Ultra Modern Transport Infrastructure� Taxes� Competitive operating costs� Quality of life

Privileged Geo-Strategic position

International Business Hub

Access to 1.3 billion customers

FREE ACCESS TO THE WORLD´S

LARGEST MARKETS (EU-27)

•High GDP per capita (over

$30,000).

•More than 500 Million


•More than 500 Million

consumers.

•Advantages to operate in EU:

•Intra-European duty free

market.

•The free movement of

goods & services, capital and

persons.

•Single currency: EURO.

IDEAL HUB TO DO BUSINESS WITH NORTH AFRICA:

Bilateral Treaties signed with North Africa countries:

•4 Agreements to Avoid Double Taxation (Egypt, Morocco, Algeria,

Tunisia).

•5 Agreements for Protection And Promotion Of Reciprocal

Investments (Algeria, Egypt, Libya, Morocco, Tunisia).


• Euro-Mediterranean

Association Agreements

with Egypt, Israel, Jordan,

Lebanon, Morocco, Tunisia

and Algeria for the gradual

liberalization of trade in the

Mediterranean area.Euro-Mediterranean Association Agreements

Agreements for Protection and Promotion of Reciprocal Investments

Agreements to Avoid Double Taxation

IDEAL HUB TO DO BUSINESS

WITH LATIN AMERICA:

•Bilateral Treaties signed with

Latin America countries:

•11 Agreements to Avoid

Double Taxation (Argentina, Bolivia, Brazil, Chile, Colombia, Cuba, El

Salvador, Ecuador, Mexico, Trinidad &


Salvador, Ecuador, Mexico, Trinidad &

Tobago, Venezuela).

•19 Agreements for

Protection and Promotion

of Reciprocal

Investments (Argentina, Bolivia, Colombia, Costa Rica, Cuba, Chile, Ecuador,

El Salvador, Guatemala, Honduras, México,

Nicaragua, Panamá, Paraguay, Perú, Rep.

Dominicana, Trinidad and Tobago, Uruguay

and Venezuela).

•Excellent communications and infrastructure: Madrid concentrates

around 35% of total air traffic between Europe & Latin America.

Agreements for Protection and Promotion of Reciprocal Investments

Agreements to Avoid Double Taxation

Favourable fiscal system for foreign investors and R+D activities:

•And the 2nd most favourable fiscal incentives for R&D among OECDcountries for large companies and SMEs.

Rate of Tax Subsidies for R&D, 2008

Incentives programmes

Note: Tax subsidies are calculated as 1 minus the B index. For example, in Spain, 1 unit of R&D expenditure by large firms results in 0.349 unit of tax relief. Source: OCDE, Sep. 2009

...not only for R&D activities, but also for:

� Hiring and training of workers � New business start-ups� SME’s

Internationalization

...and generous and attractive Grants & Incentive Schemes

Incentives programmes

� Internationalization� Renewable energies� Tourism

Incentives search engine Incentives search engine Incentives search engine Incentives search engine

available on our webavailable on our webavailable on our webavailable on our web

www.investinspain.orgwww.investinspain.orgwww.investinspain.orgwww.investinspain.org

Highly skilled labor force

Spain ranks 3rd in Europe in ratio of number of persons with a

scientific/technical tertiary education, just behind Finland and

Denmark.

Human Resources in Science and Technology with tertiary education

Human capital

education

0

2,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

Ger

man

y

UK

Fra

nce

Spa

in

Italy

Pol

and

Tur

key

Net

herla

nds

Bel

gium

Sw

eden

Rom

ania

Gre

ece

Sw

itzer

land

Den

mar

k

Fin

land

Hun

gary

Bul

garia

Cze

ch R

epub

lic

Aus

tria

Por

tuga

l

Lith

uani

a

Slo

vaki

a

Slo

veni

a

Est

onia

Latv

ia

Cyp

rus

Luxe

mbo

urg

Icel

and

Mal

ta

HR

ST

0%

5%

10%

15%

20%

Ratio H

RS

T / Population

HRST Aged 25-65 RatioSource: Eurostat, 2009.

Labour costs more competitive than main European economies.

IT Salary Comparison (€)

50000

60000

Comparability of IT staff Labor Cost within the EU Countries

Human capital

0

10000

20000

30000

40000

50000

Denm

ark

Sweden

Deutsh

land

Norway

Nether

lands

Finlan

dFra

nce

Belgium

United

Kin

gdom

Irelan

d

Italy

Austri

a

Spain

Greec

eCze

ch R

epub

lic

Experienced (5-9 year experience) Junior (1-4 year experience)

Source: IDC based on payscale 2008Note: IDC applied the average 2007 euro pound exchange rate which depreciates UK salaries

Spain is the 2nd largest High-

Speed Network in the EU with

1,600 km (9,131 miles)

Spain will be the European

leader in 2010.

Railway Network

Ultra Modern Transport Infrastructure

17

250 airlines have scheduled flights, operating out of the country’s 49 airports, being Madrid and Barcelona the

main hubs.

Airport Network

Spain is the 2nd largest EU highway network with 14,689

km (9,131 miles). At the end of 2010, Spain will be

the European leader.

Highway Network

Ultra Modern Transport Infrastructure

18

Excellent maritime connections,

with 53 ports on both the Atlantic

and the Mediterranean coasts,

putting Spain in 4th, with 3 ports

among the Top-10 ports of

containers in Europe

(Barcelona, Algeciras and

Valencia).

Main Port Facilities

•Favourable tax rate on corporate income (30% and 25% for SMEs), under the USA and OECD average.

•An attractive allowance and deduction system in corporate tax (18,4% effective rate).

•One of the lowest VAT within EU countries (16%), with a reduced VAT of 7%. On July, the VAT will increase up to 18% and 8% respectively, as a way to reduce the deficit.

Taxes

3934,4 34 32,5 31,4 29,8 28

25*

05

1015202530354045

Statutory tax rate on corporate income (%), 2009

Source: Invest in Spain, from data provided by Eurostat, 2009.

*For qualified SMEs, Corporate Tax will be 20% for the first 120,000€ and 25% onwards.For non SMEs the corporate tax is 30%.

0,0

5,0

10,0

15,0

20,0

25,0

30,0

35,0

Hourly labor cost. 2006

Mad

rid

Kuw

ait

Seo

ul

Dub

ai

Lon

don

Tok

yo

Kong

Par

is

Bom

bay

Dub

lin

Mos

cow

Mila

n

TY

ork0,0

300,0

600,0

900,0

1200,0

1500,0

1800,0

2100,0Office Utilization cost (€/year an m2)

Competitive operating costs

Pol

and

Hun

gary

Sw

eden

Bel

gium

Fra

nce

Aus

tria

EU

-15

EU

-25

Spa

in

Por

tuga

l

Cze

ch R

Mad

rid

Kuw

ait

Seo

ul

Dub

ai

Lon

don

Tok

yo

H. K

ong

Par

is

Bom

bay

Dub

lin

Mos

cow

Mila

n

N.T

Yor

k

Fra

nce

Spa

in

Irel

and

Italy

Luxe

mb.

UK

Ger

man

y

Net

herla

nd

Bel

gium

Por

tuga

l

UE

-15

0,0

2,0

4,0

6,0

8,0

10,0

12,0

Electricity prices for industrial use (€ cents/Kwh)

Source: Eurostat 2008 Source: Cost of Living Survey 2007, Mercer Human Research Consulting

Source: Eurostat 2007

Fra

nkfu

rt

Bar

celo

na

Mos

cow

Lond

on

Tok

yo

Mila

n

Par

is

N.Y

ork

Dub

lin

Am

ster

dam

Mad

rid

0,0

20,0

40,0

60,0

80,0

100,0

120,0

140,0Cost of life, 2007 (N. York =2007)

Source: Eurostat 2008

Expatriate friendly climate

� The Economist ranks the quality of life in Spain third in the world in terms of a set of social, political, cultural and economic parameters

� Spain was chosen in 2007 as the best place to live and to work in by European CEOs (Source: The Financial Times)

� Largest number of International Schools in Europe (Source: European Council

Quality of life

� Largest number of International Schools in Europe (Source: European Council of Int’l Schools)

� Outstanding & modern health system with very high standards

� Favorable fiscal regime for expatriates

� High employee retention

� Law enforcement: Assurance & stability in business and social life

� Excellent climate, first-class gastronomy, wide range of cultural and leisure activities

Investment opportunities in biotechnology, pharmacology and life sciences in Spain

Spain is currently one of the world’s leaders inrenewable energy, especially biofuels.

Important traditional sectors such as food, textiles andpackaging have obtained excellent returns by

Bioenergy

Industrial

Business opportunities

22

packaging have obtained excellent returns byimplementing bioprocesses on their production lines.

The need to adapt to European standards in order toexport food products has spawned an entire network ofcompanies in Spain in the food safety and quality area.

The extensive acceptance of functional food in Spainmeans the market is growing continuously.

Industrial Bioprocesses

Food Quality and Biosafety

Functional Food


Current methods and production processes are expected tobe insufficient to cover the pharmaceutical sector’sgrowth. Biopharming could help to cover the surplusdemand with low cost production processes.

Biopharming


23

The demand for prevention, control and treatmentsystems for animal health have increasedsignificantly. Furthermore consumers are calling forreliable and detailed information on the origin of the foodthey eat.

Thanks to the widespread application of marinebiotechnology in various sectors, Spain can offer foreigninvestors a substantial number of potential customers in thisarea. They include companies in the broader pharma sector.

Animal Health

Marine Biotechnology


Spain has advanced centres, both private and public, forthe development of new technologies in the field ofadvanced therapy for different types of illness.

In fact Spain offers a fecund environment based on itsintegrated healthcare system and easy access to patients

AdvancedTherapies

Oncology


24

integrated healthcare system and easy access to patientsfor innovation in oncology.

Furthermore several Spanish pharmaceutical companieshave commenced innovative projects in the field ofnanomedicine, including those connected with theNanofarma Project.

Foreign firms have access to an extensive biomedicalresearch and practice network including numerous hospitalswhere they can obtained genetic samples and carry outclinical trials on new drugs and therapies.

Oncology

Nanomedicine

PersonalizedMedicine


The over-65 population is growing rapidly and predictionssay Spain will eventually be the country with the highestproportion of senior citizens in the world.

Moreover the Spanish generics market is currently growingat about 20% per year. The reasons for this growthinclude government support and promotion by the

Ageing Medicine

Generics and Biosimilars


25

include government support and promotion by thecompanies concerned.

The high quality-cost ratio of clinical testing in Spain isa very attractive feature of the local market compared toother European countries. There are many under-servedniches in the hospital market – such as hospitals specialisingin surgery.

Spain is becoming a centre of innovation in which ITpersonnel, biomedical engineers and doctors havejoined forces to develop new technologies with high addedvalue.

Biosimilars

Clinical Trials

HealthcareTechnologies


There is a bioinformatic services research and applicationnetwork led by the Spanish Bioinformatics Institute,which is established in key areas of the country.

Spain is going through a cultural shift with respect to

Bioinformatics


26

Spain is going through a cultural shift with respect toventure capital profits for small and mid-size companies.Venture Capital

� Sector overview

� Main participants

� Research infrastructure

� Public and private support

� Intellectual property rights

Biotechnology

� R&D spending

� Partnerships

� Scientific workforce

� International comparisons

27

Biotechnology: overview

Scientific Production

� In 2008 Spain produced 3.8% of the world’s scientific articles and 8.5% of European articles.

� It is 5th by scientific production in the EU15 (2008).

Development 2000-2008

Source: Relevance of Biotechnology in Spain 2009, Genoma Spain.

In this period Spain added 1.4 percentagepoints to its worldwide share of scientificpublications.

28

Company creation & employment growth

� During 2000-2008 the number of biotech companies (BC) rose 239% up to 275

� The number of employees at companies strictly biotech (BC) has increased 930% (48% CAGR) up to reach 4,240 employees.


29

Spanish biotechnology accounts directlyand indirectly for more than 104,000 jobs(including all the 669 companies withbiotech related activities).

Between 2007 and 2008 the growth ratewas 18%.

Dynamic creation of jobs

Source: Relevance of Biotechnology in Spain 2009, Genoma España; ASEBIO 2008 Report.

Strong SPIN-OUTs culture

� Every year public institutions create between 10 and 12 new companies.

� This rate increased to 13-15 biotech companies (BC) in 2006-2008.


Faster growth of strictly biotech companies

Source: Relevance of Biotechnology in Spain 2009, Genoma España

Since 2000 the number of BC has grown to275 in 2008.

Nonetheless industrial companies usingbiotechnology (IBC) have also grown.

The combined total of BC and IBC hasgrown 70% during the period.

30

Breakdown of biocompanies by activity

� Of all strictly biotech companies (BC), two-thirds focus on healthcare.

� Most industrial companies related to biotechnology (IBC) focus mainly on agro-food.



31

Distribution of biotechnology companies and biotech user companies by region

� After Madrid and Catalonia, Andalucía is the autonomous region with the higher number of strictly-biotech companies (BC).

�Most biotech companies are located in Madrid (22.18%), Catalonia (21.4%) and Andalucía (13.23%). Together they account for slightly more than 50% of the national total.



32

Distribution of candidate drugs in the development phase by area of application

� Most products in development are targeting oncology.

� They are followed at a distance by neuroscience and infectious diseases.

Oncology

Neurosciences

Infections diseases


Source: ASEBIO 2008 Report

33

Infections diseases

Others

Inflamation

Cardiovascular

Dermatology

Inmunology

Hepatology

Gastroenterology

Hematology

Institutions promoting biotechnology

A public sector foundation that fosters technologicaldevelopment, knowledge transfer and innovation in thebiotechnology arena.

The Spanish Association of Bioenterprises is a meeting placefor the sector and it represents its members in contacts withthe regional, national and European authorities.

Biotechnology: major participants

Source: corresponding websites.

The main goals of the Spanish Society of Biotechnology are topromote development of biotechnology, to organisescientific meetings and to encourage research in otherscientific areas.

The Association of Science and Technology Parks of Spain isfinanced by the Ministry of Science & Innovation. It representsscience and technology parks in the 17 autonomousregions. Its job is to organise this innovative network atnational level.

34

Leading sources of government finance

�Research & Development Programme: loans and grants to cover materials, personnel, investments and collaboration.

� Torres Quevedo Programme: grants to encourage hiring of research personnel (doctorates and technicians).

� Science & Technology Infrastructure Programme: aid for communal infrastructure and


Programme: aid for communal infrastructure and equipment in science and technology parks.

CDTI: supporting business development

Source: MICINN; CDTI, websites.

Research & Development Programme:� Credits to finance companies� Consortium and collaboration finance,

both national and international�Mixed risk capital (public + private

funds), NEOTEC.

35

Spain’s bio-regions

� At present there are 6 bio-regions, coinciding with the major centres of technical innovation.

• BioBasque, Basque Country

• Biocat, Catalonia

• Madrid Biocluster

• BioVal, Valencia

• Andalucia BioRegion


• Andalucia BioRegion

• Canary Islands BioRegion

Co-operative innovation

Source: bio-region websites

The respective governments and business organisations promote joint projects by companies in conjunction with the associated science centres.

36

Technology parks boost Spanish innovation

� By 2008 nearly 80 science and technology parks had emerged in the 17 autonomous regions.

� These innovation centres contain more than 4500 companies of which 600 are related to biotech activities.

� The number of companies created was up 21% compared to the previous year.

Biotechnology: research infrastructure

Source: APTE annual report for 2008.Members and associates of APTE (Association of Science and Technology Parks of Spain)

37

AFFILIATE MEMBERS

FULL MEMBERS

Full membersAffiliatemembers

Spanish biotech companies with global impact

Its innovative medical products based on cell therapy weredesignated by the EU for “rare-disease treatment” (orphandrugs). Cellerix has a pipeline with products in clinicalphases II and III.

Based on molecules obtained from marine organisms, n,Pharmamar developed Yondelis, an anti-tumour drug,


Source: corresponding websites.

Pharmamar developed Yondelis, an anti-tumour drug,which has been successfully launched in the market worldwide.

The Neuron Group BhP develops drugs and nutraceuticalsfor prevention of Alzheimer's. And its BioIndustrial lineworks with Abengoa Bioenergy on important projects todevelop biofuels.

NeoCodex has unique technology for advanced genomicstudies. This helped it to expand in competitive markets suchas the USA and Japan.

38

Some foreign biotech companies in Spain

This company came to Spain 10 years ago. It has 150 seniorstaff here who are mainly working on clinical studies andmarketing its products based on R&D in the US.

Celgene specialises in bio-healthcare R&D. It will invest €45mon advanced therapies and regenerative medicine at theCelgene Institute of Translational Research Europe (CITRE) in


Source: corresponding websites; www.farodevigo.es; Invest in Spain

Celgene Institute of Translational Research Europe (CITRE) inSeville.

Discoverer and developer of innovative products and servicesfor treating serious disorders, especially rare diseases. It setup a sales office in Madrid in January 2009 and has awarehouse for domestic distribution.

This company produces recombinant monoclonalantibodies from mammiferous cell cultures. Lonza Biologicsset up a production facility in Galicia, investing about €170m.

39

Strong financial support for biotechnology

� In 2000-2008 public subsidies grew at 22% (CAGR).

�Grants for R&D, innovation and infrastructure projects exceeded €500m.

� The government’s innovation corporation (ENISA) and the Technological and the Industrial Development Centre made more investments in biotech.

Biotechnology: Funding

more investments in biotech.

Growth in 2000-2008


In 2007 public sector subsidies forbiotech were up 57% year-on-year.

40

The central and regional governments are providing strong support for R&D

� In 2008 the Ministry of Science & Innovation’s financing of biotech infrastructure and R&D came to more than €350m.

� The regions also contributed more than €100m, a substantial amount.



41

In 2008 total public sector aid for biotech R&D exceeded €1 billion

� Including subsidies and credits, aid for biotech projects and infrastructure accounted for 45% of total public spending.

� In 2007 investments and total public spending on biotech exceeded €1.3 billion.



42

Venture Capital

� In 2005-2008 biotech investments were five times the amount invested in 2000-2004.

� In 2008 such investment came to €122m. The average operation entailed €1m and a company with less than 20 employees.


Private sector R&D spending


The annual increase in private R&D spending was25 percentage points more than publicinvestment.

Shareholders’ equity invested by biotechcompanies accounted for more than half the totalamount.

43

Other finance options: ICO credits and the alternative stock market (MAB in Spanish)

The government’s ICO credit line:

� Up to 100% project finance.� The maximum amount financed depends on company size. The limit

is €10m.� The repayment period can be up to 12 years with a 3-year grace


Source: www.ico.es; www.bolsasymercados.es

44

� The repayment period can be up to 12 years with a 3-year grace period.

MAB is a market for small-cap companies that want to expand. The rules are specifically designed for such companies and the processes and costs are appropriate:

� It facilitates access to finance by small-cap companies� It gives the company greater public exposure� It determines the company’s value� It provides shareholders with liquidity

Growing innovative capacity

� Between 2000 and 2006 the number of international patent applications tripled.

� Between 2007 and 2008 the number of applications at the Spanish patent office doubled.

�We identified 117 discoveries made by Spanish biotech companies (ASEBIO members) in the year 2008, an increase of 40% over the previous year.

Biotechnology: intellectual property rights

increase of 40% over the previous year.

Boost for Spanish innovation


Between 2006 and 2007 the total numberof patent applications increased 70%.

45

Europe and the USA are Spain's major biotech partners

�Of those that set up partnerships with Spanish biotech companies, the rest of European countries and the USA account for 22% and 7% respectively, of the total partnerships signed.

� In 2008, 68 partnerships were formed.

Biotechnology: partnerships


46

A solid base of qualified staff

� Spain is the fourth European country in terms of science and technology graduates, surpassed only by Germany, France and Britain

� The total number of those working on biotech R&D nearly doubled in 2007-2008.

� At the end of 2008 these researchers and technicians

Biotechnology: Human Capital

� At the end of 2008 these researchers and technicians numbered 21,210.

Greater weight of public entities


The public sector accounts for75% of researchers.

The Spanish governmentprovides 60% of the resourcesassigned to public researchcentres.

47

GROWTH

� We are still in the expansion phase and the biotech sector is growing 3.5 percentage points faster than the USA.

� Compared to the EU15, Germany, USA and Canada, Spain is the fastest growing country in terms of biotech in the last seven years.

Biotechnology: international comparisons

� In 2004-2006 Spain was the fastest growing country in terms of the number of companies working on or using, biotechnology (up 53%) and strictly-biotech companies (up 30%) among the OECD members, ranked 8th by the total number of companies and 9th in R&D expenditures.

�Spain is the top country within the European Union, with 0.7% of cultivatable land used for GMO (genetically modified organisms).

�Worldwide it is third by number of experimental fields – behind the USA and Canada.


48

International presence of Spanish biotechnology

� Companies affiliated to ASEBIO have in total over 60 subsidiaries in 26 countries of 4 continents.

Biotechnology: international comparisons


49

About ASEBIO

ASEBIO: SPANISH BIOINDUSTRY ASSOCIATION

� Founded 10 years ago and with over 175 members, ASEBIO is the National Spanish Bioindustry Association, a private, non-profit organization.

� It has acted as a meeting and promotion platform for those

About ASEBIO

� It has acted as a meeting and promotion platform for thoseorganizations interested in the development of the nationalbiotecnology sector in Spain.

� Apart from private companies, ASEBIO’s member base consist of universities, scientific parks, research institutionsand others.

� ASEBIO belongs to EuropaBio, the European Association of Bioindustries.

About Invest in Spain

THE ONE-STOP SHOP FOR INVESTORS IN SPAIN.

� Invest in Spain is the leading government organization that supports foreign companies seeking to set up or expandtheir business in Spain. We are a ONE-STOP-SHOP for investors.


� We provide comprehensive, efficient and confidential consultation at no cost during all stages of the investment process, from planning and evaluation, to start-up and post-investment services.

� Our services include tailor-made reports, analyses and information about issues such as tax rules, availability of grants and incentive and help with project cost appraisals. We guarantee professional guidance by assigning a dedicated project manager to each project.

Relocation

Retention

� Up-to-date information

� Practicalpointers fordoing business

� Organization of visits to potential

� Provision of institutional contacts

� Planning for retaining investments

Expansion

Growthstrengthening

of loyalty

Operation

Support to new invertors

Installation

Benchmarking& Attraction

Pre-Installation

Investor Services


� Market studies

� Spanish offer

doing business

� Availability of grants and incentives

� Help with costappraisals

potential sites

� Identification of partners

� Finding specialist advisors

� Help with licences & permits

contacts

� Fostering expansion

� Network development

investments

� Relocation studies (within Spain)

98 Trade Commissions in Spanish Embassiesworldwide


Our support network abroad consists of 98 Trade Commissions in Spanish Embassies worldwide.

For further information please contact:

Ana Arias UronesINVEST IN SPAIN

Email: [email protected]

David FernándezASEBIO

Email: [email protected]

Thank you very much

Email: [email protected] Email: [email protected]

spain: business opportunities in the biotechnology sector · spain ranks 3rd in europe in ratio of...

Documents